Press Releases Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Delayed Nasdaq Other stock markets 20:51:23 02/05/2024 BST			5-day change	1st Jan Change
7.62 ^USD	+4.67%		+3.96%	-23.03%

04-04	British billionaire Joe Lewis fined $5 million by US judge for insider trading	RE
04-04	Multibillionaire Joe Lewis to face US sentencing for insider trading	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04-01	BU
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	03-18	BU
Tango Therapeutics to Participate in Upcoming Investor Conferences	03-06	BU
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	03-05	AQ
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	01-31	AQ
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01-05	AQ
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	01-04	PR
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	01-04	AQ
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	01-03	AQ
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	11-13	AQ
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights	11-08	AQ
Tango Therapeutics to Present at the Jefferies London Healthcare Conference	11-07	AQ
MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023	27/10/23	AQ
Thinking about buying stock in Nikola Corp, Eos Energy Enterprises, Applied Therapeutics, Tango Therapeutics, or Cabaletta Bio?	25/09/23	PR
Tango Therapeutics : Corporate Presentation	20/09/23	PU
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	18/09/23	AQ
Medivir s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase clinical Study	12/09/23	AQ
Tango Therapeutics : Corporate Presentation	11/09/23	PU
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study	11/09/23	AQ
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers	06/09/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Press Releases

Filters